HAIKOU CITY, China, Nov. 13,
2018 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE MKT:
CPHI) ("China Pharma," the "Company" or "We"), an NYSE American
listed corporation with a fully-integrated specialty
pharmaceuticals subsidiary based in China, announced today the
launch of its health product Noni Enzyme ARARATO® to the
market.
Noni, also known by its scientific name as Morinda
citrifolia, is a fruit-bearing tree in the coffee family,
Rubiaceae. Its native range extends across tropical islands of the
South Pacific, and Hainan Island,
China. The strong-smelling fruit
has been used in traditional medicine, and in the consumer market,
it has been introduced as a supplement in various forms, such as
health products, skin products, and juices.
"Noni Enzyme is rich in Proxeronine and Proxeronase, which is a
natural, healthy and nutrition-rich food supplement. Noni was
approved by the Chinese Ministry of Health as a new resource food
in 2010," said Ms. Zhilin Li, China Pharma's Chairman and
CEO. Ms. Li continued, "Our product ARARATO® uses high quality
noni fruit grown locally in Hainan
Island as its raw material, and enjoys the quality assurance
system environment back-up by our facility as a pharmaceutical
manufacturer. We are committed to providing a high quality Noni
enzyme product to the market."
The launch of ARARATO® represents a strategic development for
our company to expand into the health product market. We believe
that with the aging of the Chinese population, the growth of the
middle class population, and the strengthening of national
health awareness, we are in a good position to explore health
products - along with our core business of pharmaceutical
products - to leverage use of our facilities and sales
channels to meet market needs.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical
company that develops, manufactures and markets a diversified
portfolio of products, focused on conditions with high
incidence and high mortality rates in China, including cardiovascular, CNS,
infectious, and digestive diseases. The Company's cost-effective,
high-margin business model is driven by market demand and supported
by new GMP-certified product lines covering the major dosage forms.
In addition, the Company has a broad and expanding nationwide
distribution network across all major cities and provinces in
China. The Company's wholly-owned
subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd.,
is located in Haikou City,
Hainan Province. For more
information about China Pharma Holdings, Inc., please visit
www.chinapharmaholdings.com. The Company routinely posts important
information on its website.
Safe Harbor Statement
Certain statements in this press release constitute
forward-looking statements for purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. Any statements set forth above that are not historical facts
are forward-looking statements that involve risks and uncertainties
that could cause actual results to differ materially from those in
the forward-looking statements. Such risks and uncertainties may
include, but are not limited to: the achievability of financial
guidance; success of new product development; unanticipated changes
in product demand; increased competition; downturns in the Chinese
economy; uncompetitive levels of research and development; and
other information detailed from time to time in the Company's
filings and future filings with the United States Securities and
Exchange Commission. The forward-looking statements made herein
speak only as of the date of this press release and the Company
undertakes no duty to update any forward-looking statement to
conform the statement to actual results or changes in the Company's
expectations, except as required by applicable law or
regulation.
View original
content:http://www.prnewswire.com/news-releases/china-pharma-holdings-inc-launched-health-product-noni-enzyme-ararato-300748946.html
SOURCE China Pharma Holdings, Inc.